Host Response Profiling is the only system that analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient (i.e., the host) in response to a given cancer therapy. This proteomic profile is highly predictive of individual patient outcome, thus enabling personalized treatment planning. Host Response Profiling also identifies potential drug targets, advancing the development of novel therapeutic strategies.
OncoHost's profiling platform offers a new layer of information, enabling early identification of non-responsiveness to cancer treatments and discovery of new targets to overcome treatment resistance.
A simple predictive blood test helps your doctor tailor your treatment plan to improve the chance of success
Clinical decision support systems improve patient outcome and reduce the chance of unnecessary side effects
Approval of costly drugs only for patients most likely to respond to a given treatment
Population enrichment improves clinical trial success rate, lowers cost, & enables faster & easier regulatory approval
OncoHost’s profiling Platform provides a versatile and actionable solution for a wide range of cancers & medications, presenting a unique & appealing business proposition
OncoHost develops personalized strategies to maximize the success of cancer therapy. Utilizing proprietary proteomic analysis, we aim to understand the patient's unique response to therapy and overcome one of the major obstacles in clinical oncology today – resistance to therapy. Based on robust scientific infrastructure and a strong IP position, OncoHost is launching an extensive clinical program with leading academic and clinical partners.
Our management is comprised of an experienced multi-disciplinary team possessing a unique combination of expertise. With a deep understanding of life sciences and using a systematic approach to understand all biological aspects of disease and medication (tumor and micro-environment), we deliver a new dimension of knowledge to cancer therapy.
Sharon, MD, CEO of OncoHost. "By combining OncoHost's proprietary technology with proteomic analysis, we are able to predict how individual patients may respond to treatment. This is the first step towards developing successful personalized cancer treatment plans." OncoHost has launched an extensiveRead More>
cancer patients." "The grant and support from the BIRD Foundation represents an important milestone for OncoHost," said Dr. Ofer Sharon, CEO of OncoHost. "We are committed to develop a system for the early identification of resistance to cancer therapy in patientsRead More>
P.O.Box 446, 3 Hamelacha, Binyamina, Israel
Israel Tel: +972 52 333 5429
Fax: +972 485 37554